R&D Closed & Collaborative – January to February 2026 January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.
R&D More than manufacturing: The value of a patient-centric CDMO For a biopharmaceutical company, contracting a CDMO that considers itself accountable to the patients can deliver a tangibly different experience.
R&D Clinical research demands agile CROs An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.
Digital Veeva Commercial Summit 2025: On Data harmonisation with Ale... At Veeva Commercial Summit in Madrid, we spoke with Alexander Ulrich, Global Head of System Integration & Data Ownership at Boehringer Ingelheim.
Partner Content Partner Content Citius Oncology Signs Exclusive Commercialization Agreement ... Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
R&D Driving innovation through partnership at AstraZeneca, with ... Nikhil Mutyal, head of search and evaluation for respiratory and immunology at AstraZeneca, discusses partnership and external innovation at LSX.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.